OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
NEW YORK, Jan. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. (“Seattle Genetics”) (NASDAQ:SGEN) between October 27, 2016 and December 23, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. If you purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/seattle-genetics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period, Seattle Genetics made false and/or misleading statements and/or failed to disclose that: (a) its product in development, vadastuximab talirine, presents a significant risk of fatal hepatoxicity; (b) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (c) as a result, the Company’s statements were materially false and misleading at all relevant times.
On December 27, 2016, Seattle Genetics issued a press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine.
If you suffered a loss in Seattle Genetics you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
